|Articles|December 22, 2010

Quiz on PTSD, Violence, and Trauma

Which treatment was found to be detrimental to patients with PTSD? What is the Brøset Violence Checklist used for? These questions and more in this week's quiz.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

ByLeah Kuntz

June 29th 2026

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

ByLeah Kuntz

May 26th 2026

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

ByAmanda Koire, MD, PhD

May 18th 2026

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

ByJames Rachal, MD

May 16th 2026

MD-MOSAIC: A Proposed Psychiatrist’s Guide for Assessment of Altered Mental Status in Mechanically Ventilated Patients With Critical Illness

ByElisabeth Dietrich, MD,Ruhan Farsin, MD,Melissa P. Bui, MD

April 28th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Quiz on PTSD, Violence, and Trauma

Related Content

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

MD-MOSAIC: A Proposed Psychiatrist’s Guide for Assessment of Altered Mental Status in Mechanically Ventilated Patients With Critical Illness

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vol 43, Issue 7 - Interactive

Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

Beyond Deprescribing: A Formula for Excellent Clinical Care

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA